Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.

Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE

Publication: Switzerland : Springer Healthcare Communications
Original Publication: Heidelberg : Springer 2011-

Introduction: The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clinical response, PRO measures and baseline characteristics could help clinicians individualize treatment plans. The objective of this analysis was to examine changes in signs, symptoms and quality-of-life (QoL) PRO measures in patients who maintained complete skin clearance through ≥ 3 years in the phase 3 VOYAGE 1 trial.
Methods: A descriptive post hoc analysis of data from VOYAGE 1 was conducted to compare baseline characteristics of patients who maintained complete skin clearance (Psoriasis Area and Severity Index [PASI] = 0 for ≥ 156 consecutive weeks) versus patients who did not. Mean scores for individual domains of the Dermatology Life Quality Index (DLQI) and Psoriasis Symptom and Sign Diary (PSSD) were evaluated in patients who maintained complete skin clearance, and baseline characteristics of patients who achieved PRO scores of DLQI = 0/1 and PSSD = 0 were compared with those who did not.
Results: Of the 329 patients included in this post hoc analysis, 73 (22.2%) maintained PASI = 0 for ≥ 156 weeks. This group had a numerically lower proportion of patients at baseline with obesity, depression or previous biologic treatment and a higher proportion who had never smoked. Patients who maintained PASI = 0 generally achieved positive DLQI and PSSD outcomes, though some impact of residual disease was observed, largely related to the DLQI "Symptoms and feelings" sub-scale and PSSD components "Dryness," "Redness" and "Itch." Patients reporting continued disease impact (despite sustaining PASI = 0) had greater disease severity at baseline versus those achieving DLQI = 0/1 and PSSD = 0.
Conclusion: Clinical measures alone do not capture the full patient experience. While both QoL and clinical symptoms are responsive to highly effective treatment, a subset of patients with complete clinical response is still impacted by their psoriasis. Further investigation into this population is warranted.
Trial Registration: ClinicalTrials.gov, NCT02207231.
(© 2024. The Author(s).)

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60. (PMID: 10.1001/jama.2020.400632427307)
Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–17. (PMID: 10.1016/j.jaad.2016.11.04128057360)
Validity of Outcome Measures. Clinical review report: guselkumab (Tremfya) (Janssen Inc). Indication: for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy: Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.
Reimus JL, Vingerhoets AJ, Soons PH, Korstanje MJ. Suffering in psoriasis patients: its relation with illness severity and subjective well-being. Int J Dermatol. 2007;46:1042–5. (PMID: 10.1111/j.1365-4632.2007.03191.x17910711)
van Ee I, Deprez E, Egeberg A, Augustin M, Conrad C, Corazza V, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022;36:403–12. (PMID: 10.1111/jdv.1782934816508)
Finlay AY, Khan GK. Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6. (PMID: 10.1111/j.1365-2230.1994.tb01167.x8033378)
Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333–7. (PMID: 10.1111/jdv.1210623425140)
Feldman SR, Mathias SD, Schenkel B, Colwell HH, McQuarrie K, Randazzo B, et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary. J Dermatol Dermatol Surg. 2016;20:19–26. (PMID: 10.1016/j.jdds.2015.07.004)
Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, et al. Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies. Am J Clin Dermatol. 2019;20:155–64. (PMID: 10.1007/s40257-018-0396-z30417277)
Papp KA, Lebwohl MG. Onset of action of biologics in patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2018;17:247–50. (PMID: 29537442)
Warren RB, Brnabic A, Saure D, Langley RG, See K, Wu JJ, et al. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. Br J Dermatol. 2018;178:1064–71. (PMID: 10.1111/bjd.1614029171861)
Ferrándiz C, Carrascosa JM, Boada A. A new era in the management of psoriasis? The biologics: facts and controversies. Clin Dermatol. 2010;28:81–7. (PMID: 10.1016/j.clindermatol.2009.03.00220082956)
Gooderham MJ, Elewski B, Augustin M, Iversen L, Torii H, Burge R, et al. Effect of ixekizumab on patient reported outcomes and quality of life in patients with moderate-to-severe plaque psoriasis: 5-year results from the UNCOVER-1 and -2 studies. J Drugs Dermatol. 2021;20:394–401. (PMID: 10.36849/JDD.582133852247)
Strober B, Tada Y, Mrowietz U, Lebwohl M, Foley P, Langley RG, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188:749–59. (PMID: 10.1093/bjd/ljad03536967713)
Gisondi P, Gottlieb AB, Elewski B, Augustin M, McBride S, Tsai TF, et al. Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2). Dermatol Ther (Heidelb). 2023;13:315–28. (PMID: 10.1007/s13555-022-00861-436509889)
Gooderham M, Pinter A, Ferris LK, Warren RB, Zhan T, Zeng J, et al. Long-term, durable, absolute psoriasis area and severity index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36:855–65. (PMID: 10.1111/jdv.18010351745569314097)
Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185:1146–59. (PMID: 10.1111/bjd.2056834105767)
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31:213–20. (PMID: 10.1111/jdv.1400727739123)
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol. 2005;125:659–64. (PMID: 10.1111/j.0022-202X.2005.23621.x16185263)
Armstrong A, Puig L, Langley R, Tsai TF, Song M, Wasfi Y, et al. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial. J Dermatol Treat. 2019;30:27–34. (PMID: 10.1080/09546634.2017.1364694)
Lacour JP, Bewley A, Hammond E, Hansen JB, Horne L, Paul C, et al. Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL). Dermatol Ther (Heidelb). 2020;10:1099–109. (PMID: 10.1007/s13555-020-00428-132761560)
Gerdes S, Brau B, Hoffmann M, Korge B, Mortazawi D, Wiemers F, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48:1854–62. (PMID: 10.1111/1346-8138.1612834510527)
Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9:e027535. (PMID: 10.1136/bmjopen-2018-027535310059396500315)
Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114–23. (PMID: 10.1111/bjd.1575028635018)
Gordon KB, Han C, Li S, You Y, Song M, Fakharzadeh S, et al. Correlation of physician-assessed psoriasis area and severity index scores with patient-reported psoriasis symptoms and signs diary scores among patients with moderate-to-severe psoriasis: results from VOYAGE 1 and VOYAGE 2 studies. J Psoriasis Psoriatic Arthritis. 2019;4:147–52. (PMID: 10.1177/2475530319854781)
Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2021;35:450–7. (PMID: 10.1111/jdv.1681632662540)
Honma M, Cai Z, Burge R, Zhu B, Yotsukura S, Torisu-Itakura H. Relationship between rapid skin clearance and quality of life benefit: post hoc analysis of Japanese patients with moderate-to-severe psoriasis treated with ixekizumab (UNCOVER-J). Dermatol Ther (Heidelb). 2020;10:1397–404. (PMID: 10.1007/s13555-020-00441-432910360)
Ryan C, Puig L, Zema C, Thompson EHZ, Yang M, Wu E, et al. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. J Am Acad Dermatol. 2023;88:169–72. (PMID: 10.1016/j.jaad.2021.12.03234954285)
Viswanathan HN, Chau D, Milmont CE, Yang W, Erondu N, Revicki DA, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. 2015;26:235–9. (PMID: 10.3109/09546634.2014.943687)
Miyagi T, Kanai Y, Murotani K, Okubo Y, Honma M, Kobayashi S, et al. Itch as a critical factor in impaired health-related quality of life in patients with plaque psoriasis achieving clear or almost-clear skin: analysis of the single-arm, open-label, multicenter, prospective ProLOGUE study. JAAD Int. 2022;8:146–53. (PMID: 10.1016/j.jdin.2022.06.013359420629356143)
Soliman M. Patient-reported disease severity and quality of life among Arabic psoriatic patients: a cross-sectional survey. Clin Cosmet Investig Dermatol. 2020;13:601–9. (PMID: 10.2147/CCID.S269909329438987473981)
Liluashvili S, Kituashvili T. Dermatology life quality index and disease coping strategies in psoriasis patients. Postepy Dermatol Alergol. 2019;36:419–24. (PMID: 10.5114/ada.2018.75810316162156791166)
Puig L, Costanzo A, de Jong E, Torres T, Warren RB, Wapenaar R, et al. Guselkumab-treated patients with plaque psoriasis who achieved complete skin clearance for ≥156 consecutive weeks: a post hoc analysis from the VOYAGE 1 clinical trial. Am J Clin Dermatol. 2024;25:315–25. (PMID: 10.1007/s40257-023-00816-137804472)

Keywords: Biologics; Clinical evaluation and treatment; Psoriasis; Quality of life

ClinicalTrials.gov NCT02207231

Date Created: 20240817 Latest Revision: 20241005

20241005

PMC11393255

10.1007/s13555-024-01245-6

39153060